|
Forecast
Period
|
2024-2028
|
|
Market
Size (2023)
|
0.20
billion
|
|
CAGR
(2024-2029)
|
2.21%
|
|
Fastest
Growing Segment
|
Type
II Diabetes Segment
|
|
Largest
Market
|
Abu
Dhabi
|
Market Overview
UAE
Human Insulin Market has valued at USD 0.20 billion in 2023 and is anticipated
to witness an impressive growth in the forecast period with a CAGR of 2.21% through
2029. Human insulin refers to a type of insulin that is identical
to the insulin produced by the human body. Insulin is a hormone that plays a
crucial role in regulating blood glucose (sugar) levels. It is produced by the
beta cells of the pancreas, and its primary function is to facilitate the
uptake of glucose by cells for energy use. Human insulin has a specific
molecular structure composed of two polypeptide chains, an A chain, and a B
chain, linked by disulfide bonds. The amino acid sequence of human insulin is
precisely the same as the insulin naturally produced in the human body. Human
insulin can be produced through recombinant DNA technology. This involves
inserting the human insulin gene into bacteria, yeast, or other cells capable
of producing the insulin protein. The cells then replicate and express the
human insulin protein, which is harvested and purified for therapeutic use.
Human insulin is typically
administered via subcutaneous injections using insulin syringes, insulin pens,
or insulin pumps. The choice of insulin type and administration method depends
on the individual's treatment plan, lifestyle, and healthcare provider
recommendations.
Ongoing
research and development in the field of diabetes and insulin therapies
contribute to the introduction of innovative and more effective insulin
products. The availability of advanced and improved insulin formulations can
drive market growth. Advances in insulin delivery systems, such as insulin
pens, pumps, and smart devices, enhance patient convenience and adherence. The
adoption of these technologies can stimulate market growth. Changes in lifestyle, including
sedentary habits and unhealthy dietary patterns, contribute to the increasing
incidence of diabetes. Urbanization and lifestyle changes can drive the demand
for insulin in the population. The
aging population is often associated with an increased risk of developing
diabetes. As the demographic profile of the UAE shifts towards an older age
structure, the demand for insulin for diabetes management is likely to rise.
Key Market Drivers
Advancements in Insulin Therapies
Analog insulins are designed
to mimic the body's natural insulin production more closely than traditional
human insulins. Rapid-acting analogs, such as insulin lispro, aspart, and
glulisine, offer quicker onset and shorter duration of action, allowing for
more precise control over postprandial glucose levels. Long-acting insulin
analogs, including insulin glargine and insulin detemir, provide a more stable
and prolonged release of insulin, offering a basal level of coverage and
reducing the risk of hypoglycemia compared to traditional long-acting insulins.
Ultra-rapid insulins, like insulin lispro U100 and U200, are engineered to have
an even faster onset of action and a shorter duration than traditional
rapid-acting insulins. These can be particularly useful for post-meal glucose
control. Inhaled insulin formulations, such as Afrezza, offer an alternative to
injectable insulins. Administered through an inhaler, inhaled insulin provides
a rapid onset of action and may be preferred by some patients who are averse to
injections.
Smart insulin pens are
equipped with Bluetooth or other connectivity features that allow them to sync
with mobile apps or glucose monitoring devices. These pens can track insulin
doses, provide reminders, and offer data insights to both patients and healthcare
providers. Closed-loop systems combine continuous glucose monitoring (CGM) with
an insulin pump to automatically adjust insulin delivery based on real-time
glucose levels. This technology aims to mimic the function of the pancreas more
closely, providing better glucose control. Biosimilar insulins are biologic
products that are highly similar to existing insulin therapies. These
alternatives offer potential cost savings and increased access to insulin
treatments.
Insulin pump technologies
have seen advancements, including smaller and more discreet designs, improved
infusion sets, and features such as predictive low glucose suspension (PLGS) to
prevent hypoglycemia. Some research is focused on the development of
dual-hormone artificial pancreas systems that deliver both insulin and
glucagon. This approach aims to provide more precise control over blood glucose
levels. Ongoing research explores novel formulations, such as oral insulin and
stabilized injectable formulations, to improve the absorption and stability of
insulin, potentially offering additional options for patients. This factor will
help in the development of the UAE
Human Insulin Market.
Growing Aging Population
The risk of developing
diabetes tends to increase with age. As individuals age, their bodies may
become less efficient in producing or utilizing insulin, leading to a higher
prevalence of diabetes, particularly type 2 diabetes. This, in turn, drives the
demand for insulin as a therapeutic option. The aging population is often
associated with a higher incidence of diabetes. Factors such as sedentary
lifestyles, poor dietary habits, and genetic predispositions can contribute to
the development of diabetes in older individuals, necessitating insulin therapy
for proper glycemic control. Type 2 diabetes, which is more common in older
adults, often requires insulin therapy as the disease progresses. The aging
population, therefore, contributes to the increasing demand for human insulin,
especially as a part of the treatment regimen for individuals with type 2
diabetes. With advancements in healthcare and improved living conditions,
people are living longer. The extended life expectancy increases the likelihood
of chronic health conditions, including diabetes, necessitating ongoing
management and treatment, often involving insulin.
Aging is associated with
changes in insulin sensitivity, insulin resistance, and pancreatic function.
These physiological changes can result in a higher prevalence of diabetes among
older adults, leading to an increased need for insulin therapy. Older adults
may experience multiple comorbidities and complications related to diabetes.
Insulin therapy becomes crucial in managing blood glucose levels effectively,
preventing complications, and improving overall health outcomes. Healthcare
systems often focus on public health strategies to address the needs of aging
populations. This may include diabetes management programs that highlight the
importance of insulin therapy in maintaining health and quality of life for
older individuals. Advancements in geriatric medicine and healthcare practices
for older adults may contribute to better diabetes management, including the
appropriate use of insulin therapy tailored to the needs of elderly patients.
This factor will pace up the demand of the UAE Human Insulin Market.
Lifestyle Changes and Urbanization
Urbanization
often brings about changes in lifestyle, with individuals adopting more
sedentary behaviors. Lack of physical activity is a key risk factor for the
development of type 2 diabetes, prompting an increased demand for insulin as a
treatment option. Urbanization is frequently associated with the availability
of processed and high-calorie foods, leading to unhealthy dietary habits. Poor
nutrition and overconsumption of sugary and fatty foods contribute to the
rising prevalence of diabetes, necessitating insulin therapy for glycemic
control. Urbanization is often linked to an increase in obesity rates. Obesity
is a major risk factor for insulin resistance and the development of type 2
diabetes. The growing prevalence of obesity worldwide has resulted in a higher
demand for insulin among individuals with diabetes. Urban living is often
associated with increased stress levels due to factors such as fast-paced work
environments, long commutes, and other stressors. Chronic stress can contribute
to insulin resistance, making insulin therapy necessary for managing diabetes.
Studies
have indicated that the risk of diabetes is often higher in urban areas
compared to rural settings. Factors such as lifestyle changes, dietary
patterns, and reduced physical activity in urban environments contribute to the
higher demand for insulin. Urbanization is accompanied by improved access to
healthcare facilities, making it easier for individuals to seek medical
attention and receive a diabetes diagnosis. Increased access to healthcare
contributes to early detection of diabetes and a subsequent rise in insulin
therapy prescriptions. Urban environments are often hubs for health awareness
campaigns and educational programs. As people become more informed about the
risks of diabetes and the importance of early intervention, there is a greater
likelihood of seeking medical advice and initiating insulin therapy when
needed.
Urban
lifestyles are characterized by a reliance on processed and convenience foods,
which are often high in refined sugars and carbohydrates. This dietary shift
contributes to insulin resistance and the need for insulin therapy among
individuals with diabetes. Some regions experiencing rapid urbanization,
particularly in developing countries, face a diabetes epidemic. The transition
from traditional diets to more Westernized, urban diets is a major contributing
factor, leading to an increased demand for insulin. Urban areas typically have
more advanced healthcare infrastructure, including hospitals, clinics, and
pharmacies. This infrastructure supports the diagnosis, treatment, and
management of diabetes, contributing to the overall demand for insulin. This factor will
accelerate the demand of the UAE Human Insulin Market.
Download Sample Report
Key Market Challenges
Market
Access and Pricing
The regulatory framework in the UAE,
including pricing regulations and market access policies, can impact the entry
of insulin products into the market. Stringent regulatory requirements may
create barriers for some manufacturers, affecting the availability of diverse
insulin options. The pricing of insulin products is influenced by various
factors, including production costs, research and development expenses, and
market competition. Manufacturers may face challenges in setting prices that
are both competitive and reflective of the value provided by their products. Access
to insulin is often dependent on health insurance coverage. Challenges may
arise if insurance coverage is limited or if there are restrictions on
reimbursement for certain insulin formulations. This can affect affordability
for patients and influence market access. The cost of insulin is a critical
factor that directly impacts patients' ability to access and adhere to their
prescribed treatments. Affordability challenges can lead to decreased
compliance and negatively affect health outcomes. Importing insulin products
and distributing them across the UAE can incur additional costs, including
customs duties, transportation, and storage expenses. These factors can
contribute to pricing challenges and affect market access. The level of competition among insulin
manufacturers and suppliers in the UAE can influence pricing strategies.
Intense competition may drive manufacturers to adopt aggressive pricing, while
limited competition could lead to higher prices. Changes in currency exchange
rates can impact the cost of importing insulin, especially if manufacturers or
distributors operate in currencies with fluctuations against the UAE dirham.
This can contribute to pricing challenges in the market.
Patient Adherence
Some
individuals may perceive insulin therapy as a last resort or associate it with
the progression of their disease. Fear of injections, stigma surrounding
insulin use, or concerns about social judgment can hinder patient acceptance
and adherence. Fear or anxiety related to needles and injections is a common
issue that can affect patient adherence to insulin therapy. This phobia may
lead to avoidance or irregular administration of insulin doses. Insulin therapy
often involves complex dosing regimens, including multiple injections per day
or a combination of different insulin types. The complexity of these regimens
can overwhelm some patients, leading to errors or non-adherence. Insufficient
education and awareness about diabetes and the importance of insulin therapy
can contribute to poor adherence. Patients need a clear understanding of their
condition, the rationale behind insulin therapy, and proper administration
techniques. The cost of insulin and associated supplies can be a barrier to
adherence, especially if patients face financial constraints or have limited
access to health insurance coverage. Affordability issues may lead to rationing
of insulin or discontinuation of therapy. Cultural factors and beliefs can
influence health-related behaviors. In some cases, cultural attitudes toward
illness, treatment, or traditional remedies may impact a patient's willingness
to adhere to prescribed insulin therapy. Patients with limited health literacy may
struggle to understand healthcare information, including instructions for
insulin therapy. This can hinder their ability to manage their condition
effectively.
Key Market Trends
Development of Biosimilar
Insulins
Biosimilar
insulins have the potential to offer cost savings compared to their reference
products. This can enhance accessibility to insulin therapy, especially in
regions where affordability is a critical factor for patients. The development
and approval of biosimilar insulins provides healthcare professionals and
patients with a broader range of treatment options. This diversification can be
beneficial in tailoring diabetes management to individual patients’ needs. The
introduction of biosimilar insulins fosters competition within the market.
Increased competition may lead to competitive pricing and improved access to
insulin therapies, benefiting patients and healthcare systems. Regulatory
agencies, including those in the UAE, have been providing frameworks for the
approval and commercialization of biosimilar products. Regulatory support
facilitates the entry of biosimilar insulins into the market, contributing to
their adoption. As biosimilar insulins gain acceptance and successful track
records in various international markets, their adoption becomes more likely in
other regions, including the UAE. Pharmaceutical
companies, both multinational and local, are investing in the development of
biosimilar insulins. This reflects advancements in biotechnological
capabilities and the growing expertise in biosimilar development.
Segmental Insights
Indication Insights
In 2023, the UAE Human Insulin Market largest share was held by Type
Il Diabetes segment and is predicted to continue expanding over the coming
years.
Type II diabetes is more
prevalent globally, and this trend is often reflected in many regional markets,
including the UAE. Most diabetes cases in the population may be attributed to
Type II diabetes, leading to a higher demand for insulin products targeting
this segment. Type II diabetes is often associated with lifestyle factors such
as poor diet, sedentary behavior's, and obesity. If these factors are prevalent
in the UAE population, there may be a higher incidence of Type II diabetes,
contributing to a larger market share for insulin treatments targeting this
segment. Type II diabetes is more commonly diagnosed in adults, and as the
population ages, the prevalence of Type II diabetes tends to increase. If the
demographic composition of the UAE includes a larger proportion of adults, this
could influence the dominance of the Type II Diabetes segment in the insulin
market. Public health initiatives and healthcare strategies often prioritize
the prevention and management of Type II diabetes due to its association with
modifiable risk factors. This focus may lead to a greater emphasis on insulin
products for Type II diabetes within the market.
Type Insights
In 2023, the UAE Human Insulin Market largest share was held by pre-mixed
segment and is predicted to continue expanding over the coming years. Pre-mixed insulin offers convenience and simplicity in terms of
administration for patients. It combines both short-acting and long-acting
insulins in one formulation, reducing the need for multiple injections. This
ease of use can make pre-mixed insulin an attractive option for both patients
and healthcare providers. The convenience of pre-mixed insulin may contribute
to improved adherence to treatment plans. Patients are more likely to adhere to
prescribed insulin regimens when the administration is straightforward,
potentially leading to better glycaemic control. For individuals with diabetes,
reducing the number of daily injections can be a significant factor in choosing
a particular insulin regimen. Pre-mixed insulin allows for fewer injections
compared to using separate short-acting and long-acting insulins. Pre-mixed
insulin formulations are often well-suited for individuals with Type II
diabetes, which is more prevalent globally. The convenience and simplicity of
pre-mixed insulin can make it an effective option for managing blood glucose
levels in Type II diabetes patients.
Products Insights
In 2023, the UAE Human Insulin Market largest share was held by Insulin Pens segment in the forecast period and is predicted to continue
expanding over the coming years. Insulin
pens are known for their simplicity and ease of use. They are convenient for
both patients and healthcare providers, allowing for precise and easy
administration of insulin doses. Insulin pens offer a more user-friendly
experience compared to traditional vial and syringe methods. They are portable,
discreet, and do not require extensive preparation, making them suitable for
patients who need to administer insulin in various settings. Insulin pens
provide a more accurate and consistent dosage delivery, reducing the likelihood
of dosage errors. This is particularly important for individuals who require
precise control of their blood glucose levels. The convenience and simplicity
of insulin pens can contribute to better patient adherence to prescribed
insulin regimens. Patients may find it easier to incorporate insulin pen use
into their daily routines, resulting in more consistent treatment. The design of insulin pens, which often
includes fine needles and a less intimidating appearance compared to syringes,
may help reduce needle phobia and injection fear among patients.
Download Sample Report
Regional Insights
The Abu Dhabi region dominates
the UAE Human Insulin Market in 2023. Abu Dhabi is the capital and economic hub
of the United Arab Emirates (UAE). The region's economic strength and
development can attract healthcare investments and foster a robust
pharmaceutical industry, including the insulin market. The presence of advanced
healthcare infrastructure, medical facilities, and research institutions in Abu
Dhabi may contribute to the dominance in the insulin market. Access to
state-of-the-art medical facilities often attracts pharmaceutical companies and
supports market growth. The Abu Dhabi government has implemented specific
initiatives or policies to promote healthcare, diabetes management, or the
pharmaceutical sector, this could positively impact the human insulin market in
the region. The population density and demographic composition of Abu Dhabi may
play a role. If there is a higher prevalence of diabetes or a larger population
in need of insulin therapy in Abu Dhabi compared to other regions, it could
lead to market dominance.
Recent Developments
- In April 2022, NeoBiocon, a
collaboration between Biocon Ltd, a leading biopharmaceutical company in Asia,
and Dr. B.R. Shetty, Chairman of Neopharma in the UAE, has announced a
strategic partnership with Novartis Middle East FZE. The collaboration aims to
market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in the
United Arab Emirates (UAE). This venture is set to enhance NeoBiocon's product
portfolio in the metabolics segment, offering significant benefits to
individuals with diabetes in the UAE. Vildagliptin, an oral anti-diabetic
agent, provides consistent and robust blood sugar control for patients with
type 2 diabetes. As a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, it
is known for its weight-neutral effects and a low risk of hypoglycemia. NeoBiocon
has secured approvals from the Ministry of Health-UAE for the marketing of
Jalra and Jalra-M in the country, with the launch scheduled for January 2016.
Key Market Players
- Novo Nordisk Pharma Gulf FZ-LLC
- Sanofi UAE
- Baxter International UAE
- B. Braun Medical Gulf FZ – LLC
- Eli Lilly and Company UAE
- Becton Dickinson And Company UAE
- Gulf Pharmaceutical Industries P.S.C. (Julphar)
|
By Indication
|
By Route of Administration
|
By Type
|
By Onset Time
|
By Products
|
By Region
|
|
Type I Diabetes
Type Il Diabetes
|
Subcutaneous
Nasal
Intravenous
Transdermal
Oral
Others
|
Basal
Bolus
Pre-mixed
Biosimilar
Traditional
|
Rapid Acting
Short-Acting
Intermediate Acting
Long Acting
Ultra-long Acting
Pre-Mixed
Inhaled
|
Insulin Pens
Insulin Pumps
Infusion System
Injection
|
Dubai
Abu Dhabi
Sharjah
Rest of UAE
|
Report Scope:
In this report, the
UAE Human Insulin Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Human Insulin Market, By Indication:
o Type I Diabetes
o Type Il Diabetes
- Human Insulin Market, By Route of Administration:
o Subcutaneous
o Nasal
o Intravenous
o Transdermal
o Oral
o Others
- Human Insulin Market, By Type:
o Basal
o Bolus
o Pre-mixed
o Biosimilar
o Traditional
- Human Insulin Market, By Onset Time:
o Rapid Acting
o Short-Acting
o Intermediate Acting
o Long Acting
o Ultra-long Acting
o Pre-Mixed
o Inhaled
- Human Insulin
Market, By Products:
o Insulin Pens
o Insulin Pumps
o Infusion System
o Injection
- Human Insulin Market,
By region:
o
Dubai
o
Abu
Dhabi
o
Sharjah
o
Rest
of UAE
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies presents in the UAE Human Insulin
Market.
Available Customizations:
UAE Human
Insulin Market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
UAE Human Insulin Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]